Non-small Cell Lung Cancer
Conditions
Brief summary
Surgery may be the best treatment choice for early stage non-small cell lung cancer. And VATS major lung resection have been preferred as a standard radical procedure for early stage non-small cell lung cancer (NSCLC).This study aim to investigate the outcome of VATS major lung resection for lung cancer as a real-world study in china.
Detailed description
Surgery may be the best treatment choice for early stage non-small cell lung cancer. And VATS major lung resection have been preferred as a standard radical procedure for early stage non-small cell lung cancer (NSCLC).This study aim to investigate the outcome of VATS major lung resection for lung cancer as a real-world study in china.This is a multicenter, prospective study, aimed To evaluate the short-term and long- term outcome of VATS major lung resection for early stage lung cancer. Patients will be followed up every 3 months for 3 years.
Interventions
PROCEDUREThoracoscopy/VATS
Patients undergo major lung resection by thoracoscopic surgery or video assisted thoracoscopic surgery.
Sponsors
Peking University People's Hospital
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Preoperative criteria: i) non-small cell lung cancer is suspected, ii) clinical stage I/II (3) Intraoperative criteria: i) Histologically confirmed NSCLC, ii) resected by VATS or converted open lobectomy,sleeve lobectomy or pneumonectomy and nodal dissection/sampling. (4) No prior ipsilateral thoracotomy (prior diagnostic thoracoscopy is allowed). (5) No prior chemotherapy or radiation therapy for any malignant diseases. (6) Expected postoperative FEV1.0\>=800 mL and PaO2\>=65 torr. (7) Performance status of 0 or 1. (8) Sufficient organ functions. (9) Written informed consent.
Exclusion criteria
1. Active bacterial or fungous infection. 2. Simultaneous or metachronous (within the past 5 years) double cancers. 3. Women during pregnancy or breast-feeding. 4. Interstitial pneumonitis, pulmonary fibrosis, or severe pulmonary emphysema. 5. Psychosis. 6. Systemic steroids medication. 7. Uncontrollable diabetes mellitus. 8. Uncontrollable hypertension. 9. History of severe heart disease, heart failure, myocardial infarction within the past 6 months or attack of angina pectoris within the past 6 months.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| morbidity and mortility rate | 3 moths | perioperative complications and death rates of the group |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Rate of loco-regional and systemic recurrence | 3y | To evaluate the rate of loco-regional and systemic recurrence of the group. |
| Pulmonary function | 6 months after surgery | to evaluate the pulmonary function as measured by expiratory flow rate of the group 6 months postoperatively. |
| Postoperative hospital stay. | 3 months postoperatively | to evaluate the postoperative hospital stay of the group. |
| Disease-free survival | 3y | To evaluate Disease Free Survival (DFS) of the group. |
| overall survival | 3 months postoperatively | to evaluate the overall survival rate of the group. |
| converted rate | 3 months | the rate of converted thoracotomy |
| Postoperative drainage duration | 3 months postoperatively | to evaluate the postoperative drainage duration of the group. |
Countries
China
Contacts
Primary ContactJun Wang, MD
Outcome results
None listed